White Papers
Our work in White Papers
-
Taking a Broader View of “Junk Insurance”
Christen Linke Young explains the dangers of junk insurance.
-
The Economic Case for Public Investment in Stem Cell Research
Our analysis shows the measure resulted in over 56,000 jobs created and added approximately $10 billion to the state’s economy.
Categorized in -
Making ACA Enrollment More Automatic for the Newly Unemployed
USC-Brooking Schaeffer Initiative researchers lay out strategies to help the newly uninsured transition to Medicaid or the ACA individual market.
-
Estimating Potential Spending on COVID-19 Care
Schaeffer Initiative researchers quantify the estimated costs of COVID-19 care in the U.S. in a new report.
-
Is the U.S. Ready to Quickly Vaccinate its Population Against COVID-19?
Once a COVID-19 vaccine is developed, achieving universal immunization will require a cohesive, multi-faceted vaccination strategy across the U.S. healthcare system.
Categorized in -
Getting Americans Back to Work (and School) With Pooled Testing
To reopen safely, employers need to identify workers who have active COVID-19 infections and do so at reasonable cost. Pooled testing for the coronavirus is an effective, scalable tool for doing so.
Categorized in -
How Well Could Tax-Based Auto-Enrollment Work?
Auto-enrollment into health insurance coverage is an attractive policy that can drive the U.S. health care system towards universal coverage.
-
How Would Sharing Rebates at the Point-Of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D?
If cost-sharing were based on net price it would provide meaningful financial relief to many Part D beneficiaries.
-
Health Technology Assessment for the U.S. Healthcare System
A white paper from the USC Schaeffer Center-Aspen Institute Advisory Panel on health technology assessment in the U.S. Experts explore how to better link the price of health technologies to the benefits they provide to patients while ensuring a sustainable healthcare ecosystem that supports innovation.
Categorized in -
The Association Between Drug Rebates and List Prices
Drug rebates and list prices are positively correlated: On average, a $1 increase in rebates is associated with a $1.17 increase in list price.
Categorized in